
    
      OBJECTIVES: I. Assess the therapeutic role of tamoxifen in patients with inoperable
      hepatocellular carcinoma in terms of overall survival and quality of life.

      OUTLINE: This is a randomized, double blind, placebo controlled study of tamoxifen. Patients
      are randomized to one of 3 treatment arms. Arm I: Patients receive placebo orally twice daily
      for one year. Arms II and III: Patients receive tamoxifen, at 1 of 2 different doses, orally
      twice daily for one year. Quality of life is assessed before treatment and then monthly
      thereafter. Patients are followed monthly until death.

      PROJECTED ACCRUAL: This study will accrue 300 patients.
    
  